GoodRx is monitoring seven potential FDA drug approvals in 2025, including a possible expanded label for Ozempic. Here are this year's most anticipated approval decisions, according to a GoodRx ...

In a disclaimer, GoodRx noted that the list was created by prioritizing "first-in-class medications and vaccines that are expected to have a significant impact on human health." "This was defined ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco. SANTA MONICA, Calif., January 10, 2025--GoodRx (Nasdaq: GDRX), the leading ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...